CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
